Sheryl McCoy

1.2k total citations
14 papers, 882 citations indexed

About

Sheryl McCoy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Sheryl McCoy has authored 14 papers receiving a total of 882 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Sheryl McCoy's work include Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sheryl McCoy is often cited by papers focused on Gastric Cancer Management and Outcomes (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sheryl McCoy collaborates with scholars based in United States, Australia and Ukraine. Sheryl McCoy's co-authors include James L. Abbruzzese, Jacqueline Benedetti, John S. Macdonald, Carol M. Moinpour, Donna K. Pauler, Charles D. Blanke, Cecilia M. Fenoglio‐Preiser, Tomislav Dragovich, Jiang Wang and Ken S. Zaner and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Surgery and Statistics in Medicine.

In The Last Decade

Sheryl McCoy

14 papers receiving 859 citations

Peers

Countries citing papers authored by Sheryl McCoy

Since Specialization

Citations

This map shows the geographic impact of Sheryl McCoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheryl McCoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheryl McCoy more than expected).

Fields of papers citing papers by Sheryl McCoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheryl McCoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheryl McCoy. The network helps show where Sheryl McCoy may publish in the future.

Co-authorship network of co-authors of Sheryl McCoy

This figure shows the co-authorship network connecting the top 25 collaborators of Sheryl McCoy. A scholar is included among the top collaborators of Sheryl McCoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheryl McCoy. Sheryl McCoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study 2014 ·Journal of Thoracic Oncology ·Silvia Novello, Giorgio V. Scagliotti, (unknown), Ihor Vynnychenko, Constantin Volovăț, Claus-Peter Schneider, Fiona Blackhall, Sheryl McCoy, Yong-Jiang Hei, David R. Spigel	14
2	The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors 2013 ·BMC Cancer ·Lee S. Rosen, Lara Lipton, Timothy Price, (unknown), Ralph V. Boccia, Herbert I. Hurwitz, Joe Stephenson, Lori J. Wirth, Sheryl McCoy, Yong-Jiang Hei, Cheng‐Pang Hsu, Niall C. Tebbutt	11
3	International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1 2012 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor–Eliade Ciuleanu, (unknown), Mircea Dediu, Zsolt Pápai-Székely, Natividad Martínez-Banaclocha, Sheryl McCoy, Bin Yao, (unknown), Francesco Galimi, David R. Spigel	143
4	Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study 2011 ·BMC Cancer ·Dusan Kotasek, Niall C. Tebbutt, Jayesh Desai, Stephen Welch, Lillian L. Siu, Sheryl McCoy, Yu‐Nien Sun, Jessica Johnson, Adeboye H. Adewoye, Timothy Price	8
5	Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors 2010 ·Cancer Chemotherapy and Pharmacology ·Robert S. Benjamin, Patrick Schöffski, Jörg T. Hartmann, A. van Oosterom, Binh Bui, Justus Duyster, Scott M. Schuetze, Jean‐Yves Blay, Peter Reichardt, Lee S. Rosen, Keith M. Skubitz, Sheryl McCoy, Yu-Nien Sun, Daniel E. Stepan, Laurence H. Baker	46
6	Impact of Hospital Volume on Recurrence and Survival After Surgery for Gastric Cancer 2007 ·Annals of Surgery ·Peter C. Enzinger, Jacqueline Benedetti, Jeffrey A. Meyerhardt, Sheryl McCoy, Scott A. Hundahl, John S. Macdonald, Charles S. Fuchs	84
7	Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study 2006 ·Investigational New Drugs ·Robert P. Whitehead, Sheryl McCoy, John S. Macdonald, Saul E. Rivkin, Marcus A. Neubauer, Shaker R. Dakhil, Heinz‐Josef Lenz, Michael Tanaka, James L. Abbruzzese	11
8	A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: A Southwest Oncology Group study 2006 ·Investigational New Drugs ·Robert P. Whitehead, Sheryl McCoy, Saul E. Rivkin, Howard M. Gross, Marcel E. Conrad, Gary C. Doolittle, Robert A. Wolff, J. Wendall Goodwin, Shaker R. Dakhil, James L. Abbruzzese	55
9	Phase II Trial of Gemcitabine Plus Irinotecan In Patients With Esophageal Cancer 2006 ·American Journal of Clinical Oncology ·Stephen K. Williamson, Sheryl McCoy, David R. Gandara, Shaker R. Dakhil, Kathleen J. Yost, Jorge C. Paradelo, James N. Atkins, Charles D. Blanke, James L. Abbruzzese	8
10	Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study 2006 ·Investigational New Drugs ·James H. Doroshow, Sheryl McCoy, John S. Macdonald, Brian F. Issell, Taral Patel, Patrick Cobb, Kathleen J. Yost, James L. Abbruzzese	10
11	Phase II Trial of Erlotinib in Gastroesophageal Junction and Gastric Adenocarcinomas: SWOG 0127 2006 ·Journal of Clinical Oncology ·Tomislav Dragovich, Sheryl McCoy, Cecilia M. Fenoglio‐Preiser, Jiang Wang, Jacqueline Benedetti, Amanda F. Baker, (unknown), Susan G. Urba, Ken S. Zaner, Charles D. Blanke, James L. Abbruzzese	249
12	A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study 2005 ·Investigational New Drugs ·John S. Macdonald, Sheryl McCoy, Robert P. Whitehead, Syma Iqbal, James L. Wade, Jeffrey K. Giguere, James L. Abbruzzese	109
13	Pattern mixture models for longitudinal quality of life studies in advanced stage disease 2003 ·Statistics in Medicine ·Donna K. Pauler, Sheryl McCoy, Carol M. Moinpour	68
14	Health Status and Quality of Life in Patients With Early-Stage Hodgkin’s Disease Treated on Southwest Oncology Group Study 9133 2003 ·Journal of Clinical Oncology ·Patricia A. Ganz, Carol M. Moinpour, Donna K. Pauler, Alice B. Kornblith, Ellen R. Gaynor, Stanley P. Balcerzak, (unknown), Harry P. Erba, Sheryl McCoy, Oliver W. Press, Richard I. Fisher	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact